A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Gepotidacin (Primary) ; Gepotidacin (Primary)
- Indications Bacterial skin diseases; Gram-positive infections; Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Dec 2019 Results assessing microbiological outcomes and responses of gepotidacin in patients with ABSSSIs were published in the Antimicrobial Agents and Chemotherapy
- 03 Apr 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 30 Oct 2016 Primary endpoint has (Composite of the cure rate at the Early Efficacy Visit combined with withdrawal rate) been met.